Multibagger Selection: DeepSeek's picks
DeepSeek picked AQST, CAPR, VNDA, CGEM, MLYS with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | AQST | — | 70% | — | — |
| 2 | CAPR | — | 60% | — | — |
| 3 | VNDA | — | 65% | — | — |
| 4 | CGEM | — | 65% | — | — |
| 5 | MLYS | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +0.20% | +0.73% | 1.27x | 0 |
The model's market view
The small and mid-cap opportunity set in late 2026 is dominated by binary regulatory events in biotechnology, where FDA PDUFA dates provide specific, time-bound and verifiable catalysts. Financing conditions and FDA scrutiny remain important risks, and several of these names have already received complete response letters or faced advisory-committee skepticism. The five selections prioritize near-term regulatory decisions, adequate liquidity and scenario-based asymmetry rather than assuming approval. Reference prices are the latest regular-session closes on 2026-10-23 because consistent intraday quotes for 2026-10-26 were not available across all names.
Why each pick
AQST
Aquestive has a revenue-generating specialty-pharma base, a resubmitted NDA for Anaphylm and a March 16, 2027 PDUFA date. Q2 2026 revenue grew 38% year over year and cash of $98.5M provides more than a year of runway. Anaphylm, a sublingual epinephrine film, would be a first-in-class non-injectable rescue product if approved. The reference price is the Oct 23, 2026 regular-session close.
CAPR
Capricor is a binary late-stage biotech with a Nov 22, 2026 PDUFA date for deramiocel in Duchenne muscular dystrophy. The market cap is only about $345M, and cash and marketable securities of $237.9M fund the company through the decision. The near-term catalyst is one of the closest in the small-cap biotech calendar. The reference price is the Oct 23, 2026 regular-session close.
VNDA
Vanda is the cheapest name in the group, with a market cap of about $242.5M and an enterprise value of roughly $90M against a commercial revenue base. It has a Dec 12, 2026 PDUFA date for imdisolimab in generalized pustular psoriasis and additional pipeline catalysts. The low valuation provides high asymmetry, but cash burn and dilution risk are material. The reference price is the Oct 23, 2026 regular-session close.
CGEM
Cullinan has a Feb 27, 2027 PDUFA date for zipalertinib in EGFR exon 20 insertion NSCLC, a genetically defined lung-cancer niche with limited competition. The $925M market cap is backed by $355.9M of cash and investments, and the company has runway into 2029. The catalyst is specific and the balance sheet reduces near-term financing risk. The reference price is the Oct 23, 2026 regular-session close.
MLYS
Mineralys has a Dec 22, 2026 PDUFA date for lorundrostat in uncontrolled hypertension, a large commercial market. The $1.82B market cap and roughly $1.25B enterprise value imply substantial net cash, and the company has no near-term financing need. The catalyst is specific, but a meaningful amount of approval probability is already reflected in the valuation. The reference price is the Oct 23, 2026 regular-session close.
Other models on the same run
| Model | Picks |
|---|---|
| Perplexity | ONDS, RCAT, AEVA, SOUN, RGTI |
| Gemini 3.6 Flash High | ONDS, RCAT, AEVA, SOUN, RGTI |
| Muse Spark 1.1 | LUNR, ACHR, SOUN, SMR, FLNC |
| Grok 4.7 | CAPR, INOD, NUVB, FEIM, PAYS |
| Claude Sonnet 5.5 | AEHR, LUNR, SOUN, NNE, NVTS |
| GPT-6 | FLNC, BKSY, AMPX, INOD, ENVX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.